Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Phase III Trial Suggests Tecentriq Survival Benefit in Bladder Cancer Subgroup

Phase III Trial Suggests Tecentriq Survival Benefit in Bladder Cancer Subgroup

Oct 01, 2019
|
Andrea Anderson

Update: The Ventana's PD-L1 (SP142) Assay was classified as a complementary diagnostic for atezolizumab when the drug was granted accelerated approval from the US Food and Drug Administration in 2016. It has since become a companion diagnostic for the drug in urothelial and other cancers.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
15
Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

What's Popular?

In Cancer

  1. Oncology Venture Becomes Allarity Therapeutics, Announces Board, Executive Changes

  2. Roche's Ipatasertib, Anti-Androgen Therapy Improves Outcomes in Prostate Cancer With PTEN Loss

    Premium

  3. Merck's Keytruda, BMS's Opdivo Prolong Survival for Patients With Gastroesophageal Cancers

    Premium

  4. EMA Committee Recommends Narrower Lynparza Indication for Metastatic Prostate Cancer Than FDA

  5. Conflicting ESMO Data Raise Questions About Role of CDK4/6 Inhibitors in Adjuvant Breast Cancer

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.